Detalhe da pesquisa
1.
I-ACT for Children: helping close the gap in drug approval for adults and children.
Pediatr Res
; 93(7): 1786-1787, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271160
2.
Ensuring continued progress for development of COVID-19 therapeutics in children.
Pediatr Res
; 90(6): 1112-1114, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33603214
3.
VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.
Cell Mol Neurobiol
; 35(3): 377-387, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25392236
4.
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.
Am J Pathol
; 179(1): 12-22, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21703390
5.
Live attenuated versus inactivated influenza vaccine in infants and young children.
N Engl J Med
; 356(7): 685-96, 2007 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17301299
6.
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
Pediatr Infect Dis J
; 28(4): 267-72, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19258920
7.
Duration of protection provided by live attenuated influenza vaccine in children.
Pediatr Infect Dis J
; 27(8): 744-8, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18600188
8.
The need for rigorous evidence on medication use in preterm infants: is it time for a neonatal rule?
JAMA
; 308(14): 1435-6, 2012 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23047355
9.
Live attenuated influenza vaccine in children.
Semin Pediatr Infect Dis
; 17(4): 206-12, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17055372
10.
Sponsors meet scientists to speed pediatric medicines development.
Sci Transl Med
; 7(279): 279fs11, 2015 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25787760
11.
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
Pediatr Infect Dis J
; 23(8): 707-12, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15295219
12.
Meeting the demand for pediatric clinical trials.
Sci Transl Med
; 6(227): 227fs11, 2014 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24622511
13.
Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies.
Discov Med
; 16(89): 233-9, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24229740
14.
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
EMBO Mol Med
; 5(10): 1569-85, 2013 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24014378
15.
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Phys Med Rehabil Clin N Am
; 23(4): 821-8, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23137739
16.
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Pediatrics
; 125(1): e35-51, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20008423
17.
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Pediatr Infect Dis J
; 28(9): 835-7, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19636278
18.
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
J Pediatr
; 143(4): 532-40, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14571236